 ISELIN, N.J., Dec. 23, 2022 GLOBE NEWSWIRE Outlook Therapeutics, Inc. Nasdaq: OTLK, a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has entered into securities purchase agreements with existing institutional and accredited investors for the purchase and sale of ... The post Outlook Therapeutics Announces 25 Million Registered Direct Offering Priced At-the-Market U... 